Welcome to Chutes & Ladders

Dear readers, we at FierceMarkets would like to introduce you to a new feature, Chutes & Ladders, which we intend to make the industry's best weekly roundup of C-level hires and fires, comings and goings, up and down the ladder. And we would like your help. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (email | Twitter) and we will feature it here each Friday.

Now, without further ado, here is this week's news on moves in the executive suites.

ImmunoCellular CEO leaves abruptly

The chief executive officer of ImmunoCellular Therapeutics left abruptly Monday and the company's founder and chairman will serve as the interim CEO while ImmunoCellular searches for a replacement. Manish Singh resigned as president and director after serving as CEO since 2008. John S. Yu will take the helm for the time being and continue to serve as chairman and chief scientific officer. Company shares fell 4.3% to $2.91 Monday. After the announcement, shares fell another 36 cents in after-hours trading to $2.55. News

Manish Singh--ImmunoCellular Therapeutics
Resigned as president and director of ImmunoCellular Therapeutics

 

Jack Talley--Actinium Pharmaceuticals
President and CEO of Actinium Pharmaceuticals

 

Biotech

>
 Jack Talley became Actinium Pharmaceuticals' new president and CEO, after resigning from the same positions at EpiCept ($EPCT). Enza Guagenti will join him as the company's CFO. Story

> Rosetta Genomics ($ROSG) hired three new executives to the company's management team: Ron Kalfus joined as chief financial officer in May; Guy Malchi will jump aboard as executive vice president of corporate development in September; and Steve Miller signed on as director of marketing and reimbursement in June. Release

> INC Research announced that Chief Operating Officer Jamie Macdonald will become the company's next president and CEO on Jan. 1. Story

> BioMotiv appointed Baiju Shah as its new CEO. Release

> Dr. Alexander Milstein will serve as vice president of clinical development at Cardio3 BioSciences. Article

Pharma

> Ariana Pharma appointed Dr. Mariana Kuras as the company's chief technology officer. Release

> Lundbeck appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president with responsibility for commercialization of medicines from Lundbeck's partnership with Otsuka Pharmaceutical. Item

Medical Devices

Blue Medical appointed Noël Coopmans as its new CEO. Coopmans joins Blue Medical from eLEAF, where he served as director. Release

> Syneron Medical announced Asaf Alperovitz resigned as CFO. David Schlachet will serve as interim CFO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.